89 results about "HER2/neu" patented technology

Provided are methods for the rapid detection of ovarian cancer. The methods employ a multiplex immunoassay to detect levels of two or more of the markers EGF, G-CSF, IL-6, IL-8, CA-125, VEGF, MCP-1, anti-IL6, anti-IL8, anti CA-125, anti-c-myc, anti-p53, anti-CEA, anti-CA 15-3, anti-MUC-1, anti-survivin, anti-bHCG, anti-osteopontin, anti-PDGF, anti-Her2 / neu, anti-Akt1, anti-cytokeratin 19, cytokeratin 19, EGFR, CEA, kallikrein-8, M-CSF, FasL, ErbB2 and Her2 / neu in a sample of the patient's blood, where the presence of abnormal levels of two or more of the markers indicates the presence of ovarian cancer in the patient. An array also is provided to quantitate levels of these markers in a patient's blood. Also provided is a method of predicting onset of clinical ovarian cancer comprising determining the change in concentration over time of two or more of anti-Her2 / neu, anti-MUC-1, anti-c-myc, anti-p53, anti-CA-125, anti-CEA, anti-CA 72-4, anti-PDGFRα, IFNγ, IL-6, IL-10, TNFα, MIP-1α, MIP-1β, EGFR and Her2 / neu in a patient's blood.

This invention provides compositions and methods for treating and vaccinating against an Her2 / neu antigen-expressing tumor and inducing an immune response against dominant and several sub-dominant epitopes of the antigen.

A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2 / neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.

The present invention provides p97-antibody conjugates and related compositions and methods, which may be used in any of a variety of therapeutic methods, including methods for the treatment of cancers such as Her2 / neu-expressing and Her1 / EGFR-expressing cancers.

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2 / neu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, where the peptide comprises the p53 sequence SMPPPGTRV.

This invention relates to antibodies that specifically bind HER2 / neu, and particularly chimeric 4D5 antibodies to HER2 / neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.

The present invention describes compositions and methods for inhibiting cell proliferation comprising a prolactin receptor antagonist and an agent that inactivates the HER2 / neu signaling pathway, and methods of use thereof.

A composition or vaccine composition comprising at least one peptide that has less than 600 contiguous amino acids having 100% identity to a native sequence of CEA, HER2 / neu, MAGE2, MAGE3, or p53, the peptide further comprising at least one epitope selected from Table 6.

The present invention is directed to T cell receptors (TCR) recognizing antigenic peptides derived from Her2 / neu, in particular peptide 369, and being capable of inducing peptide specific killing of a target cell overexpressing HER2 / neu. The present invention is further directed to an antigen specific T cell, comprising said TCR, to a nucleic acid coding for said TCR and to the use of the antigen specific T cells for the manufacture of a medicament for the treatment of malignancies characterized by overexpression of HER2 / neu. The present invention is further disclosing a method of generating antigen specific T cells.

This invention provides compositions and methods for treating and vaccinating against a Her2 / neu antigen-expressing tumor and inducing an immune response against dominant in a human subject.

The invention relates to a method for producing, purifying and appraising protein, in particular to a method for expression of recombinant human her2 / neu ICD in Pasteur yeast as well as optimized large scale industrialized fermentation production and purification of the recombinant human her2 / neu ICD.

A recombinant polynucleotide encoding a Her2 / neu target antigen is provided, as is a recombinant Her2 / neu target antigen polypeptide. Also provided are methods of using such a recombinant polynucleotide to express a Her2 / neu target antigen in a cell. In addition, methods are provided for using the recombinant polynucleotide or the recombinant polypeptide to stimulate an immune response in a subject against cancer that expresses Her2 / neu. Methods of making a target antigen also are provided.

This invention provides compositions and methods for treating and vaccinating against a Her2 / neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal.

A humanized monoclonal antibody of human endophloeodal growth factor receptor 2 protein is prepared from enternal segment of HER2 / neucell through such steps as culturing the B cells of the person sensitive to HER2; fusing the said B cells with human osteoma cells (karpas 707 H); screening the external segment monoclonal anti body against HER2 cell; and amplification of the said monoclonal antibody. It features that antigen epitope is the external segment polypeptide of HER2 / neu cell for specifically binding the external segment of HER2 / neu cell, and the all gene sequences for syntehsis come from human B lymph cells and human osteoma cells.

The invention discloses an artificial oil body carrier for the targeted therapy of mastocarcinoma as well as a preparation method and an application thereof. With the preparation method, a pJO1-oleZH2 plasmid is converted to enter the host cell of escherichia coli BL21 (DE3), oleZH2 proteins are produced by induction, and oil and the oleZH2 proteins are mixed to prepare an artificial oil body carrier. Invitro and invivo experiments confirm that the artificial oil body carrier disclosed by the invention can be effectively applied to target therapy, and the oil body carried covered with fluorescent substances can reflect HER2 / neu positive cancer cells so as to specifically detect the mastocarcinoma cell excessively expressing HER2 / neu. The artificial oil body carrier has the advantages of simple preparation process, extra small environmental pollution, good stability in blood cells or serum, small volume and the like, is cheap and efficient, is convenient to operate and is easy to transport. The artificial oil body carrier can be used for covering anti-mastocarcinoma drugs of different types of oil solubility, can effectively kill mastocarcinoma cells after being coated on drugs and can carry out specific detection and target therapy for mastocarcinoma cells.

An active fragment for the mutual action between HER2 / neu and Herstation is the polypeptide with the amino acid residue sequence shown by SEQ ID No.1 or the polypeptide whose amino acid residue sequence has one or more substituted or lost, or added residues. It is also a sensitive site, where HER2 / neu molecule can be effectively suppressed. It can play its role in preparing the HER2 / neu antagonistic medicines.

This invention relates to antibodies that specifically bind HER2 / neu, and particularly chimeric 4D5 antibodies to HER2 / neu, which have reduced glycosylation as compared to known 4D5 antibodies. The invention also relates to methods of using the 4D5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.